61 related articles for article (PubMed ID: 35443927)
1. Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials.
Vanni KMM; Lyu H; Solomon DH
Rheumatology (Oxford); 2020 Apr; 59(4):709-717. PubMed ID: 31504937
[TBL] [Abstract][Full Text] [Related]
2. Non-adherence and discontinuation rate for oral and parenteral methotrexate: A retrospective-cohort study in 8,952 patients with psoriatic arthritis.
Generali E; Carrara G; Bortoluzzi A; De Santis M; Ceribelli A; Scirè CA; Selmi C
J Transl Autoimmun; 2021; 4():100113. PubMed ID: 35005587
[TBL] [Abstract][Full Text] [Related]
3. Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature.
Vermeer E; Hebing RCF; van de Meeberg MM; Lin M; de Meij TGJ; Struys EA; Jansen G; Nurmohamed MT; Ćalasan MB; de Jonge R
Curr Rheumatol Rep; 2023 Dec; 25(12):276-284. PubMed ID: 37768405
[TBL] [Abstract][Full Text] [Related]
4. A Review of Clinical Applications and Side Effects of Methotrexate in Ophthalmology.
Wang G; Peng X
J Ophthalmol; 2020; 2020():1537689. PubMed ID: 32850138
[TBL] [Abstract][Full Text] [Related]
5. International Survey to Evaluate Current Options for Subcutaneous Injection of Methotrexate (MTX) and a New Button-Free MTX Autoinjector.
Müller-Ladner U; Edwards CJ; Erkens A
Patient Prefer Adherence; 2024; 18():579-590. PubMed ID: 38463400
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety.
Téllez Arévalo AM; Quaye A; Rojas-Rodríguez LC; Poole BD; Baracaldo-Santamaría D; Tellez Freitas CM
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676680
[TBL] [Abstract][Full Text] [Related]
7. Use of parenteral methotrexate in rheumatic diseases: A systematic review.
Otón T; Carmona L; Loza E; Rosario MP; Andreu JL
Reumatol Clin (Engl Ed); 2022 Apr; 18(4):207-226. PubMed ID: 35443927
[TBL] [Abstract][Full Text] [Related]
8. Use of Parenteral Methotrexate in Rheumatic Diseases: A Systematic Review.
Otón T; Carmona L; Loza E; Rosario MP; Andreu JL
Reumatol Clin (Engl Ed); 2021 Mar; ():. PubMed ID: 33663910
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for the use of parenteral methotrexate in rheumatic diseases.
Tornero Molina J; Calvo Alen J; Ballina J; Belmonte MÁ; Blanco FJ; Caracuel MÁ; Carbonell J; Corominas H; Chamizo E; Hidalgo C; Ivorra JR; Marenco JL; Moreno Muelas JV; Muñoz-Fernández S; Nolla JM; Pérez T; Sanmarti R; Trenor P; Urrego C; Vidal J; Rosas Gomez de Salazar J
Reumatol Clin (Engl Ed); 2018; 14(3):142-149. PubMed ID: 28082032
[TBL] [Abstract][Full Text] [Related]
11. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review.
Goodman SM; Cronstein BN; Bykerk VP
Clin Exp Rheumatol; 2015; 33(2):272-8. PubMed ID: 25536122
[TBL] [Abstract][Full Text] [Related]
12. Oral methotrexate at doses 15-25 mg/week is non-inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Wang F; Tang J; Li Z; Qi Y; Li G; Wang F
Clin Rheumatol; 2022 Sep; 41(9):2701-2712. PubMed ID: 35672619
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
